We undertook a study of the characteristics and clinical impact of infections due to methicillin-resistant Staphylococcus aureus (MRSA) after liver transplantation. Of 165 patients who received liver transplants at our institution from 1990 through 1998, 38 (23%) developed MRSA infections. The predominant sources of infection were vascular catheters (39%; n = ), wound (18%; ), abdomen (18%; ), and lung (13%; ). A significant increase 15 n = 7 n = 7 n = 5 in MRSA infections (as a percentage of transplant patients infected per year) occurred over time (
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We undertook a study of the characteristics and clinical impact of infections due to methicillin-resistant Staphylococcus aureus (MRSA) after liver transplantation. Of 165 patients who received liver transplants at our institution from 1990 through 1998, 38 (23%) developed MRSA infections. The predominant sources of infection were vascular catheters (39%; n = ), wound (18%; ), abdomen (18%; ), and lung (13%; ). A significant increase 15 n = 7 n = 7 n = 5 in MRSA infections (as a percentage of transplant patients infected per year) occurred over time (
). This increase was greater among intensive care unit patients ( ) than P = .0001 P = .001 among nonintensive care unit hospital patients ( ). Cytomegalovirus seronegativity P = .17 ( ) and primary cytomegalovirus infection were significantly associated with MRSA P = .01 infections (
). Thirty-day mortality among patients with MRSA infections was 21% P = .005 (8/38). Mortality was 86% in patients with bacteremic MRSA pneumonia or abdominal infection and 6% in those with catheter-related bacteremia ( ). Thus the incidence of P = .004 MRSA infection has increased exponentially among our liver transplant recipients since 1990. These infections have unique risk factors, time of onset, and a significant difference in sitespecific mortality; deep-seated bacteremic infections, in particular, portend a grave outcome.
Etiologoies for nosocomial infections have undergone a striking change; the last decade has witnessed the emergence of gram-positive bacteria as the foremost cause of infection among hospitalized patients [1, 2] . Staphylococcus aureus is second only to coagulase-negative staphylococci as the leading source of nosocomial bloodstream infections in the United States [3] . Furthermore, methicillin resistance among S. aureus has become increasingly prevalent since the 1960s. Although there is wide institutional variation in the rate of methicillin resistance among S. aureus, up to 60% of all S. aureus strains at some centers have been shown to be methicillin-resistant [4] . More recently, the documentation of S. aureus with heteroresistance to vancomycin suggests a growing likelihood of the emergence of glycopeptide-resistant S. aureus [5] .
Studies have shown that hospitalizations associated with S. aureus infections are serious and have high resultant medical costs and death rates [6] . It was estimated that the total direct medical costs incurred by patients with S. aureus infections in New York State in 1995 was an estimated $435.5 million; the direct medical cost per patient with this infection was $32,100 [6] . Pneumonia and bacteremia represented most S. aureus in-fections, accounting for 60% of the total medical cost and 97% of all deaths among these patients [6] .
Paralleling these national and global trends in escalating rates of infections due to resistant gram-positive organisms, a dramatic increase in vancomycin-resistant enterococcal and methicillin-resistant S. aureus (MRSA) infections have also been documented among liver transplant recipients [7] [8] [9] [10] . Although a number of reports have described the spectrum of resistant enterococcal infections in these patients [7] [8] [9] , to our knowledge there has been no systematic analysis of MRSA infections among liver transplant recipients. With the threat of a fully antibiotic-resistant S. aureus looming, the clinical relevance of this bacterium is likely only to increase in the foreseeable future. This study was undertaken to discern the unique characteristics and clinical impact of MRSA infections after liver transplan tation.
Methods

Patients.
Since the establishment of a liver transplant program at the Pittsburgh Veteran's Affairs Medical Center in 1990, a prospectively maintained data bank has been in place. Variables entered into this data bank include, but are not limited to, demographic characteristics of the patients, infections, immunosuppression, rejection, and outcome.
A total of 165 consecutive patients underwent liver transplantation from 1990 through 1998. All patients received tacrolimus (FK506) and low-dose prednisone as immunosuppressive therapy, as described elsewhere [11] . Perioperative prophylaxis consisted of ampicillin and cefotaxime for 24 h. Patients allergic to penicillin received clindamycin and aztreonam. Transplant recipients not al- Infections. Infections were defined according to the criteria of the Centers for Disease Control and Prevention and as described elsewhere with reference to liver transplant recipients [12, 13] . Isolation of S. aureus from a single blood culture in the presence of clinical symptoms or signs of infection was considered true bacteremia. Bacteremia due to common skin contaminants, such as coagulase-negative staphylococci, was considered significant only if the organism was isolated from у2 blood cultures and was accompanied by clinical signs of infection, including fever, chills, or hypotension [12] . Bloodstream infection was considered primary bacteremia if it was of unknown source or related to an intravascular catheter [12] . Pneumonia was considered to be present when a new pulmonary infiltrate developed in conjunction with clinical symptoms (fever, cough, or hypoxia) and isolation of bacteria in pleural fluid or blood cultures or isolation in heavy growth in respiratory secretions [11, 13] . Peritonitis was defined as isolation of a pathogen and/or a polymorphonuclear cell count 1250/mm 3 in ascitic fluid from a percutaneous aspirate or an intraoperative specimen [11, 13] . Wound infection was defined as erythema and purulent drainage from the wound that required local debridement with or without antibiotic therapy [11, 13] .
Cultures. From January 1995 onward, monthly nasal cultures were done for all patients beginning when they were transplant candidates awaiting liver transplantation. Nasal cultures were done as reported elsewhere [10, 14] . Briefly, a culturette collection and transport system (Copan Diagnostics, New York), consisting of 2 swabs and a tube of transport medium, was used to culture the nares. One dry swab was inserted into each nares and rotated gently. The 2 swabs were then returned to the tube. Plating onto mannitolsalt medium was completed within 4 h of collection. Nasal carriage of staphylococci was defined as the presence of S. aureus in nasal samples. Patients colonized with S. aureus at any time during the study period were considered carriers [10, 15, 16] .
Statistical analysis. Patient demographics (e.g., age, underlying liver disease) and laboratory data were entered into PROPHET Statistics (AbTech, Charlottesville, VA; version 6.0). The x 2 or Fisher's exact test was used to compare categorical variables (presence or absence of an underlying condition). Continuous variables (e.g., age and operation time) were compared by use of the Student's t test or the Mann-Whitney U test. Odds ratios (ORs) for annual trends were evaluated by use of the x 2 test for trend (Epistat, Richardson, TX; version 5.3). Cumulative differences in the timing of infection were analyzed by use of the Kolmogorov-Smirnov test (Epistat).
Results
Infections.
Clinical and demographic characteristics of our study population are outlined in table 1. MRSA infections were documented in 38 (23%) of 165 consecutive liver transplant recipients. Among these 38 patients, the types of MRSA infections were as follows: primary or catheter-related bacteremia in 15 (39%), abdominal infection in 7 (18%), wound infection in 7 (18%), pneumonia in 5 (13%), urogenital infection in 2 (5%), and cholangitis and endocarditis in 1 each (3%). The 7 abdominal infections were as follows: peritonitis in 3 patients, intra-abdominal abscess in 2, and infected intraabdominal hematoma in 2. These diagnoses were established by either a culture taken from an intraoperative specimen or a percutaneous needle aspirate. The 2 urogenital infections were a scrotal abscess due to MRSA in 1 patient and an infected hydronephrosis secondary to the placement of a nephrotomy tube in another; the latter patient also had bacteremia. During the same time period, infection with methicillin-sensitive S. aureus occurred in 1 patient only, who contracted community-acquired S. aureus endocarditis 7 years after transplantation.
Overall, 26 (68%) of the 38 patients with MRSA infection were bacteremic. The sources of bacteremia were as follows: catheter-related bacteremia in 15 patients, pneumonia in 3, wound infection in 3, intra-abdominal or peritoneal infection in 3, urogenital infection in 1, and endocarditis in 1. Of all MRSA infections, 18 (47%) occurred in the intensive care unit (ICU) setting; 72% of MRSA infections in the ICU were associated with bacteremia, as were 65% of those not in the ICU.
A significant increase in MRSA infections over time (as a percentage of transplant patients infected per year) was documented ( ). ORs for the occurrence of MRSA infec-P = .0001 tions, compared with 1990, were 2.1 in 1991, 0 in 1992, 1.7 in 1993, 3.6 in 1994, 6.1 in 1995, 12.2 in 1996 ( ), 7.8 in P = .04 1997 ( ), and 21 in 1998 ( ). Although this increase P = .08 P = .01 was documented in both ICU and non-ICU settings, the in- cremental increase in percentage of MRSA isolates was greater in the ICU than in the non-ICU setting. (Overall significance for x 2 trend in the ICU was and for non-ICU, P = .001 P = ). . 17 The incidence of all nosocomial bacteremias in the hospital and in the surgical ICU from 1990 through 1998 is outlined in table 2, which shows that whereas the overall rate of nosocomial institutional bacteremias remained unchanged, the proportion of bacteremias due to MRSA increased over time.
Time of onset. The median time of onset of MRSA infection was 24 days after transplantation (range, 4 days to 6 years). Of the 38 MRSA infections, 32% (13) ). Further-P = .09 more, patients with nasal carriage tended to develop MRSA infections sooner after transplantation than did those without prior nasal carriage (median, 13 days vs. 26 days after transplantation), although the difference was not statistically significant ( ). P = . 18 There was a significant correlation between cytomegalovirus (CMV) serological status of the recipient, CMV infection, and MRSA infection. Patients with MRSA infections were significantly more likely to be seronegative for CMV before transplantation than were those without (13 ). P = .005
The length of ICU stay was significantly longer for patients with MRSA infections than for those without MRSA infections (median, 9.5 days vs. 5 days;
). Patients with MRSA P = .03 infections were significantly more likely to have additional infections than were all other patients (mean, 1.25 episodes vs. 0.68 episodes per patient;
). There was no difference P = .01 among patients in age, Child-Pugh score, underlying liver disease, operation time, UNOS (united network of organ sharing) score, or requirement of dialysis before transplantation (table  1) .
Outcome. Mortality in patients with MRSA infections was 13% (5/38) at 14 days and 21% (8/38) at 30 days. One patient with MRSA endocarditis died 5 months after the diagnosis.
Patients with MRSA infection in the ICU were significantly more likely to die (39%; 7/18) than were those not in the ICU (5%; 1/20;
). Among patients with MRSA bacteremia, P = .016 mortality was 15% (4/26) at 14 days and and 23% (6/26) at 30 days. Mortality varied significantly with the source of MRSA bacteremia. Mortality was 100% (3/3) for bacteremic patients, 67% (2/3) for those with pneumonia, 6% (1/16) for those with abdominal infection, 0% (0/3) for patients with catheter-related infection, and 0% (0/1) for those with wound and urogenital infections (  ; table 5 ). Bacteremic patients with pneu-P = .004 monia and abdominal infections were significantly more likely to die than were those with bacteremia of other sources (86% [6/7] 
vs. 10% [2/21];
). Thirty-six percent (5/14) of the P = .0047 patients with MRSA infection and nasal carriage died, compared with 0% (0/5) of those with MRSA infections without carriage ( ). Other factors analyzed as predictors of out-P = .26 come in patients with MRSA infections are outlined in table 5.
Antimicrobial treatment for MRSA infections included vancomycin as monotherapy for 21 patients and combination antistaphylococcal therapy for 16; 1 patient with surgical wound infection was treated with debridement alone and did not receive antibiotics. Of the 16 patients who received combination therapy, 8 received vancomycin/gentamicin, 6 received vancomycin/gentamicin/rifampin, 1 received vancomycin/rifampin, and 1 received vancomycin/synercid (quinupristin/dalfopristin). The median duration of gentamicin treatment, when used, was 10 days and that of rifampin was 7 days. Combination therapy was used for 60% (3/5) of the patients with pneumonia, 66% (4/6) of the patients with abdominal infections, 38% (6/16) of those with catheter-related bacteremia, 14% (1/7) of those with wound infections, and 50% (1/1) of those with urogenital infections ( ). APACHE II scores did not differ for patients P 1 .2 who received vancomycin monotherapy (15.5) versus those who received combination therapy (16.2; ). P 1 .2 Mortality at 30 days was 37.5% (6/16) among patients who ). Among patients with MRSA bacteremia, 30-day P = .06 mortality was 41% (5/12) among those who received combination therapy and 7% (1/14) among those who received vancomycin monotherapy ( ). P = .07
Discussion
Our data document a significant impact of MRSA infections on morbidity and mortality after liver transplantation. By use of strict and previously defined criteria for the diagnosis of MRSA infections, 23% of all liver transplant recipients at our center were shown to have MRSA infections; 68% of all MRSA infections were associated with bacteremia.
Our study illustrates the unique characteristics of MRSA infections in liver transplant recipients. Infections due to MRSA occurred soon after transplantation. Nearly one-third of all MRSA infections in our patients occurred within 14 days and more than one-half within 30 days of transplantation. Among our patients, a significantly greater proportion of MRSA infections compared with other bacterial infections occurred soon after transplantation period (table 4) . Furthermore, one-half of MRSA infections occurred in the ICU setting, that is, while the patient was staying in the ICU immediately after transplantation. These data are in contrast to those for nontransplant patients, in whom MRSA infections generally occur after a prolonged ICU stay [17, 18] .
Several factors could account for a greater risk of MRSA infections in the early period after liver transplantation. Liver transplant recipients have been shown to have a high incidence of staphylococcal nasal carriage before transplantation [10] . We have previously documented colonization of the anterior nares with S. aureus in 46% of the patients with end-stage liver disease who are awaiting transplantation [10] . Patients with prior nasal carriage tended to develop MRSA infections sooner after transplantation than did those without nasal carriage. Large surgical wounds, multiple drains that breach the integrity of the skin, and routine requirement of invasive monitoring devices may also increase the risk of developing MRSA infections in the early postoperative period. Additionally, impaired neutrophil function as a result of corticosteroid therapy or liver disease per se may render these patients susceptible to MRSA [10] . Specific defects associated with granulocyte function, such as decreased chemotaxis and impaired phagocytosis-associated burst activity, have been documented in the presence of liver disease [19, 20] . Indeed, it has been noted that patients with liver disease are more susceptible to MRSA infection than are other patients [18] .
A significant variation in site-specific mortality among patients with MRSA infections was documented. Mortality was 86% among patients with MRSA pneumonia or intra-abdominal infections associated with bacteremia but 6% among those with catheter-related bacteremia. This difference in mortality was independent of the APACHE II scores of the patients and the antimicrobial therapy used (vancomycin monotherapy vs. combination therapy). These data underscore the virulent nature of MRSA infection after liver transplantation, unless a readily removable source of infection, such as intravascular catheters, can be identified. Intractable hypotension and/or rapid progression to acute lung injury with refractory hypoxemia was the usual cause of death in patients with bacteremic MRSA pneumonia. Of 5 patients with MRSA pneumonia, 3 were also bacteremic and had nodular-appearing pulmonary infiltrates. In the latter 3 patients, a transesophageal echocardiogram did not reveal endocarditis. We have proposed elsewhere that S. aureus should be considered in the differential diagnosis of nodular pulmonary infiltrates in liver transplant recipients [21] .
Nasal carriage of S. aureus has been shown to be a predictor of S. aureus infections in diverse patient populations, including patients in the ICU and nosocomial setting. Although a trend toward a higher incidence of MRSA infections was identified among patients with prior nasal carriage, our data suggest that MRSA may, indeed, be an opportunistic rather than simply a nosocomial pathogen among liver transplant patients. CMVseronegative recipients and those developing primary CMV infection incurred a significantly greater risk for the development of MRSA infection after transplantation. Similar association between primary CMV infection and bacteremia and bacterial infections in transplant patients has previously been reported [22, 23] . A greater length of ICU stay for our patients with MRSA infections, on the other hand, may merely be a result, rather than a cause, of MRSA infection. Likewise, a significantly greater risk of subsequent infections for patients with MRSA infections may also be reflective of longer length of ICU stay for these patients.
Although our study was not intended to demonstrate the comparative efficacy of various antistaphylococcal regimens, it is notable that combination therapy appeared no more effective than vancomycin monotherapy. There are several possible explanations for this observation. Combination therapy was more commonly used among patients with deep-seated MRSA infections, such as those with pneumonia or abdominal infections, although this was not statistically significant. Despite frequent use of combination therapy to treat MRSA in the clinical setting, data on synergy and efficacy remain inconclusive. Gentamicin has not been shown to predictably demonstrate synergism with vancomycin in vitro for MRSA [24] . It has also been proposed that the combination of vancomycin/rifampin, particularly in the absence of gentamicin, may be indifferent or even antagonistic [25] [26] [27] [28] . However, conclusions of efficacy of a particular regimen must await clinical trials and should not be inferred from our data, given the small size and uncontrolled nature of the study.
As part of the plan to prevent transmission of MRSA infection and to control it, the following interventions have been put into place: performance of surveillance cultures to detect nasal colonization on admission after transplantation, weekly in the ICU, and monthly on the ward until discharge; administration of intranasal mupirocin twice daily for 5 days to eradicate MRSA in colonized patients; mandatory wearing of gowns and gloves by everyone who enters the room of a patient colonized or infected with MRSA; staff cohorting for MRSApositive and MRSA-negative patients in the ICU; monitoring and strict reinforcement of compliance with the aforementioned infection control measures; and use of antibiotic-impregnated vascular catheters. The long-term efficacy of these measures, however, remains to be determined.
In summary, our study documented a linear and significant trend in an overall increase in the number of MRSA infections among our liver transplant recipients. Although this experience may be unique to our center and may not be able to be extrapolated to other institutions, this rise largely parallels a wider national and global escalation in the incidence of MRSA infections. Unique characteristics of MRSA infections among liver transplant recipients include early onset after transplantation, correlation with primary CMV infection, and a high associated mortality with deep-seated infections. The cost and deaths associated with S. aureus may further increase if heteroresistance to vancomycin spreads or if glycopeptide-resistant S. aureus infections emerge. Our findings therefore have a wide clinical relevance.
